Pathologic expression of p53 or p16 in preoperative curettage specimens identifies high-risk endometrial carcinomas

被引:63
作者
Engelsen, Ingeborg B. [1 ]
Stefansson, Ingunn
Aksten, Lars A.
Salvesen, Helga B.
机构
[1] Haukeland Univ Hosp, Dept Obstet & Gynecol, N-5021 Bergen, Norway
[2] Haukeland Univ Hosp, Dept Pathol, N-5021 Bergen, Norway
[3] Univ Bergen, Gade Inst, Bergen, Norway
[4] Univ Bergen, Inst Clin Med, Bergen, Norway
关键词
endometrial carcinoma; curettage material; tumor markers; prognosis; survival;
D O I
10.1016/j.ajog.2006.02.045
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Objective: The purpose of this study was to investigate the prognostic impact of p53 and p16 expression in curettage material from patients with endometrial carcinoma. Study design: Preoperative curettage material from a population-based series of 236 endometrial carcinomas from Norway with long and complete follow-up was studied immunohistochemically for p53 and p 16 expression. Results: Pathologic expression of p53 and p16 was seen in 24% and 25%, respectively, and was significantly correlated with high International Federation of Gynecology and Obstetrics (FIGO) stage and serous/clear cell histologic subtypes. Pathologic p53 expression showed significant correlation with postmenopausal status, high grade, high tumor cell proliferation, and aneuploidy. Patients with normal expression had 85% 5-year survival compared with 51% and 50% when pathologic expression of p53 and p16, respectively. Five-year survival for patients with 2 pathologic markers was 13%, compared with 67% and 91% for 1 or no pathologic markers, respectively. Conclusion: Pathologic expression of p53 and p16 in curettage material identifies high-risk endometrial carcinoma patients with poor prognosis. (c) 2006 Mosby, Inc. All rights reserved.
引用
收藏
页码:979 / 986
页数:8
相关论文
共 32 条
  • [1] Interpretation of p53 immunoreactivity in endometrial carcinoma: Establishing a clinically relevant cut-off level
    Alkushi, A
    Lim, P
    Coldman, A
    Huntsman, D
    Miller, D
    Gilks, CB
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY, 2004, 23 (02) : 129 - 137
  • [2] Endometrial cancer
    Amant, F
    Moerman, P
    Neven, P
    Timmerman, D
    Van Limbergen, E
    Vergote, I
    [J]. LANCET, 2005, 366 (9484) : 491 - 505
  • [3] Prospective multicenter validation confirms the prognostic superiority of the endometrial carcinoma prognostic index in International Federation of Gynecology and Obstetrics stage 1 and 2 endometrial carcinoma
    Baak, JPA
    Snijders, W
    van Diermen, B
    van Diest, PJ
    Diepenhorst, FW
    Benraadt, J
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (22) : 4214 - 4221
  • [4] BARAKAT RR, 1997, PRINCIPLES PRACTICE
  • [5] Prognostic prediction of the immunohistochemical expression of p53 and p16 in resected non-small cell lung cancer
    Cheng, YL
    Lee, SC
    Harn, HJ
    Chen, CJ
    Chang, YC
    Chen, JC
    Yu, CP
    [J]. EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, 2003, 23 (02) : 221 - 228
  • [6] CREASMAN WT, 1987, CANCER, V60, P2035, DOI 10.1002/1097-0142(19901015)60:8+<2035::AID-CNCR2820601515>3.0.CO
  • [7] 2-8
  • [8] Predictors of final histology in patients with endometrial cancer
    Frumovitz, M
    Singh, DK
    Meyer, L
    Smith, DH
    Wertheim, I
    Resnik, E
    Bodurka, DC
    [J]. GYNECOLOGIC ONCOLOGY, 2004, 95 (03) : 463 - 468
  • [9] T cell development: Some cells get all the breaks
    Green, DR
    Schuler, M
    [J]. NATURE IMMUNOLOGY, 2000, 1 (01) : 15 - 17
  • [10] Prognostic value of p53 and proliferating cell nuclear antigen expression in endometrial carcinoma
    Hamel, NW
    Sebo, TJ
    Wilson, TO
    Keeney, GL
    Roche, PC
    Suman, VJ
    Hu, TC
    Podratz, KC
    [J]. GYNECOLOGIC ONCOLOGY, 1996, 62 (02) : 192 - 198